GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
Gilead (GILD) is poised for further growth, based on the FY12 guidance, maturing pipeline, and diversification. While GILD’s dominance in the HIV space in 2012-19 should remain intact with the launch of Quad Pill (R, Truvada+Cobicistat+Elvitegravir) and Complera/ Eviplera (L, Truvada + Edurant), its recent acquisition of Pharmasset and formulating experience should help it to establish supremacy in the HCV space! The top-line data of GS-7977+RBV in GT 1 HCV pts puts GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions also have started yielding results with couple of compounds reaching in to mid to late stages of clinical development - Ranexa (PhIII, ACS, Type 2 Diabetes Mellitus), GS-1101 (PhIII, CLL, iNHL), and Aztreonam (PhII, Bronchiectasis) will help it to diversify. For more detail, please read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”
COMPANIES MENTIONED
GILEAD SCIENCES
GILEAD SCIENCES
